Memorial Sloan Kettering Cancer Center: Kidney Neoplasms trials

The registry lists 34 Kidney Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 4 are open to participants now and 6 have results posted.

Phase 1 14Phase 2 17Phase 3 1Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Treatment Delivery Preference In People With Kidney CancerRecruitingNCT07872553Phase 4
• A Study of a Side Effects and Resource Navigation Program for People With CancerRecruitingNCT07646847Not applicable
• Kidney Cancer DNA RegistryRecruitingNCT02087852
• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruitingNCT00582621
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
• Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function OutcomesCompletedNCT01606787Phase 3Results posted
• BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)TerminatedNCT01453595Phase 1/2Results posted
• Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or MelanomaCompletedNCT00462982Phase 2Results posted
• Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney CancerCompletedNCT00459875Phase 2Results posted
• Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the UrotheliumCompletedNCT00397488Phase 2Results posted
• Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerActive, not recruitingNCT05239533Phase 2
• A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint InhibitorsActive, not recruitingNCT03693014Phase 2
• Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life AssessmentActive, not recruitingNCT01888198
• Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell CarcinomaActive, not recruitingNCT01582204Not applicable
• Percutaneous Renal Tumor Cryoablation Followed by BiopsyCompletedNCT01012427Phase 1
• Evaluating Renal Masses Using Ultrasound Intravenous Microbubble ContrastCompletedNCT00671411Phase 1
• Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic TumorsCompletedNCT00588276Phase 1
• Spectroscopy With Surface Coils and DecouplingCompletedNCT00581815Phase 1
• Germline Alterations of Tumor Susceptibility Genes in New York Cancer PatientsActive, not recruitingNCT00579514Not applicable
• A Study of RAD001 and Sunitinib in Metastatic Renal Cell CarcinomaCompletedNCT00422344Phase 1
• A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma PatientsCompletedNCT00421512Phase 1
• Vaccine Therapy in Treating Patients With Kidney CancerCompletedNCT00096629Phase 1
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney CancerCompletedNCT00096525Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney CancerCompletedNCT00093405Phase 2
• Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney CancerCompletedNCT00045370Phase 1
• PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerCompletedNCT00045279Phase 2
• PS-341 in Treating Patients With Metastatic Kidney CancerCompletedNCT00017329Phase 2
• ZD 1839 in Treating Patients With Metastatic Kidney CancerCompletedNCT00012337Phase 2
• Arsenic Trioxide in Treating Patients With Metastatic Kidney CancerCompletedNCT00005069Phase 2
• Interferon Alfa in Treating Patients With Advanced Kidney CancerCompletedNCT00003542Phase 1/2
• 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney CancerCompletedNCT00003390Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney CancerCompletedNCT00003342Phase 1
• Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder CancerCompletedNCT00003105Phase 1/2
• Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1/2